The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL
Cells · 2025
DOI: 10.3390/cells14171343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Joaquín Marco-Brualla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Apoptosis, Immunity and Cancer Group, Department of Biochemistry and Molecular and Cell Biology, Aragon Health Research Institute (IIS-Aragon), Unive…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Adenine, Piperidines, Dichloroacetic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Gobierno de Aragón, MCIN/AEI/10.13039/501100011033.
Abstract (Originalsprache)
Since its discovery, the BTK inhibitor ibrutinib has redefined the standard treatments for hematological cancers, such as chronic lymphocytic leukemia (CLL). However, concerns exist regarding its secondary effects in humans and its occasional lack of efficacy in certain malignancies. Therefore, combined therapies with ibrutinib have emerged as promising new approaches. In this study, we aimed to explore its therapeutic potential through different approaches. For this purpose, we combined this drug with the BH3 mimetics ABT-199 and ABT-737, which inhibit anti-apoptotic members of the Bcl-2 family, and with the PDK1 inhibitor dichloroacetate (DCA), respectively. As cell models, we used ex vivo samples from patients and also selected the in vitro CLL cell line Mec-1, generating two sub-lines overexpressing Bcl-XL and Mcl-1, a common feature in this cancer. Results demonstrated a synergistic effect for both approaches, in all tumor cells tested, for both cytostatic and cytotoxic effects. Mechanistically, the expression of Bcl-2-family proteins was explored, exhibiting increases in pro-apoptotic, but also in anti-apoptotic, proteins upon ibrutinib treatment and a relative increase in the amount of the pro-apoptotic protein PUMA after treatment with DCA. Our data provides new insights into combined therapies with ibrutinib for CLL, which further expands our knowledge and the potential of this drug for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Apoptosis, Immunity and Cancer Group, Department of Biochemistry and Molecular and Cell Biology, Aragon Health Research Institute (IIS-Aragon), University of Zaragoza, 50009 Zaragoza, Spain.
- Faculty of Pharmacy, University San Pablo-CEU, 28660 Boadilla del Monte, Spain.
- Hematology Department, Lozano Blesa Clinical Hospital, 50009 Zaragoza, Spain.
- IRMB, University of Montpellier, INSERM, CNRS, Montpellier CHU, 34295 Montpellier, France.
ORCID-Profile: Joaquín Marco-Brualla, Gemma Azaceta, Isabel Izquierdo, Martín Villalba, Isabel Marzo, Alberto Anel
Förderung
- Agencia Estatal de Investigación
- Gobierno de Aragón
- MCIN/AEI/10.13039/501100011033
- MICIU/AEI/10.13039/501100011033
Zitieren
APA
Marco-Brualla, J., Gonzalo, O., Azaceta, G., Izquierdo, I., Palomera, L., Villalba, M., Marzo, I., & Anel, A. (2025). The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL. Cells. https://doi.org/10.3390/cells14171343
Vancouver
Marco-Brualla J, Gonzalo O, Azaceta G, Izquierdo I, Palomera L, Villalba M, et al. The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL. Cells. 2025. doi:10.3390/cells14171343
BibTeX
@article{MarcoBrualla2025,
author = {Marco-Brualla, Joaquín and Gonzalo, Oscar and Azaceta, Gemma and Izquierdo, Isabel and Palomera, Luis and Villalba, Martín and Marzo, Isabel and Anel, Alberto},
title = {The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14171343}
}
EUVIMED